Skip to main content
SpringerLink
Log in

Should stroke patients with mild or improving symptoms receive tissue plasminogen activator therapy?

  • Practice Point
  • Published:

From Nature Clinical Practice Neurology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Adams H et al. (2005) Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 36: 916–923

    Article  Google Scholar 

  2. Barber PA et al. (2001) Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56: 1015–1020

    Article  CAS  Google Scholar 

  3. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group (2005) Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 46: 243–252

  4. Hack W et al. (2003) European Stroke Initiative recommendations for stroke management—update 2003. Cerebrovasc Dis 16: 311–337

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Director for Clinical Trials at the National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA

    John R Marler

Authors
  1. John R Marler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John R Marler.

Ethics declarations

Competing interests

J Marler was the project leader for the NINDS tPA Stroke Trial.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marler, J. Should stroke patients with mild or improving symptoms receive tissue plasminogen activator therapy?. Nat Rev Neurol 2, 354–355 (2006). https://doi.org/10.1038/ncpneuro0215

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0215

  • Springer Nature Limited

Search

Navigation